CYTK ▼ -1.5% - Cytokinetics, Incorporated $CYTK RBC Capital analyst Leonid Timashev raised the firm's price target on Cytokinetics to $113 from $112 and keeps an Outperform rating on the shares as part of a broader research note adjusting the firm's models and previewing Q3 results in Biotech. The quarter is shaping up reasonably well for the large caps, helped in part by additional selling days and mid-year price increases, the analyst tells investors in a research note. RBC adds however that for the commercial mid-caps, which have faced significant pressure as drug launch expectations got ahead of themselves across the board, the firm would not expect the quarter's performance alone to be enough to fully turn sentiment around, even though it "may help restore confidence in select stories". 08-OCT-2026 10:55 AM ET